Hydreight Technologies Signs Binding Letter of Intent to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership

Not for distribution to United States newswire services or for
dissemination in the United States.

VANCOUVER, British Columbia, July 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6),("Hydreight" or the "Company"), a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy distribution, is pleased to announce that it has entered into a binding letter of intent dated July 11, 2025 (the “LOI”) with Perfect Scripts LLC (“Perfect Scripts”), an arm’s length limited liability company based in Texas, in respect of a strategic partnership. Pursuant to the LOI, the parties have agreed that: (a) Hydreight will acquire an initial 5% interest in the issued and outstanding common stock in the capital of Perfect Scripts in consideration for 2,250,000 common shares in the capital of Hydreight (the “Hydreight Compensation Shares”), with each Hydreight Compensation Share issued at a deemed price equal to the greater of CAD$2.30 per share and the lowest price permitted by the policies of TSX Venture Exchange (the “Exchange”), (b) Hydreight and Perfect Scripts will partner to start a 503B pharmacy in the United States, (c) Hydreight will receive the lowest pricing for all products sold or made available by Perfect Scripts or its subsidiaries on the terms and conditions to be set out in a pharmacy services agreement to be entered into by the parties (the “Pharmacy Agreement”), and (d) Hydreight will be granted a right to (i) maintain its pro rata interest in the issued and outstanding common stock of Perfect Scripts, and (ii) acquire up to an aggregate 40% interest in the issued and outstanding securities of Perfect Scripts (collectively, the “Transaction”).

Read more at globenewswire.com